Jason Broderick

Articles

Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia

June 14th 2024

Ponatinib, chemo, and alloHSCT offer long-term survival in adult Ph+ ALL, per 4-year PONALFIL trial data at 2024 EHA Congress.

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

June 6th 2024

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC

June 5th 2024

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC

June 2nd 2024

Cabazitaxel plus abiraterone acetate and prednisone improved PSA response and extended PFS vs abiraterone acetate and prednisone in patients with mCRPC.

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC

May 5th 2024

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer

May 4th 2024

18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.

Urinary MRD Status Potentially Predictive of Recurrence in BCG-Unresponsive NMIBC

January 26th 2024

Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma

October 22nd 2023

Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Lenvatinib Plus Pembrolizumab Maintains Survival Benefit in Advanced RCC

June 5th 2023

Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.

Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI

June 3rd 2023

Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

May 2nd 2023

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC

April 29th 2023

A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.

Zoledronic Acid Lowers Risk of Fracture in mHSPC

April 28th 2023

The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.

Apalutamide Plus ADT Elicits PSA PFS Benefit in High-Risk, Biochemically Relapsed Prostate Cancer

September 11th 2022

Intensification of androgen-deprivation therapy plus apalutamide displayed promising efficacy in patients with high-risk, biochemically relapsed prostate cancer.

Atezolizumab Fails to Improve DFS in RCC Following Resection

September 10th 2022

Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.

Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC

June 7th 2022

Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.

PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPC

June 6th 2022

68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma

June 4th 2022

Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.

Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer

June 4th 2022

Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.

Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma

May 16th 2022

Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.